SEARCH

SEARCH BY CITATION

References

  • 1
    Farges O, Kalil AN, Samuel D et al. The use of ABO-incompatible grafts in liver transplantation: A life-saving procedure in highly selected patients. Transplantation 1995; 59: 11241133.
  • 2
    Demetris AJ, Jaffe R, Tzakis A et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988; 132: 489502.
  • 3
    Haga H, Egawa H, Shirase T et al. Periportal edema and necrosis as diagnostic histological features of early humoral rejection in ABO-incompatible liver transplantation. Liver Transpl 2004; 10: 1627.
  • 4
    Fidler ME, Gloor JM, Lager DJ et al. Histologic findings of antibody-mediated rejection in ABO blood-group-incompatible living-donor kidney transplantation. Am J Transplant 2004; 4: 101107.
  • 5
    Colvin RB. C4d in liver allografts: A sign of antibody-mediated rejection? Am J Transplant 2006; 6: 447448.
  • 6
    Ratner LE, Phelan D, Brunt EM, Mohanakumar T, Hanto DW. Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient. Transplantation 1993; 55: 814819.
  • 7
    Rostron A, Carter V, Mutunga M et al. A case of acute humoral rejection in liver transplantation: Successful treatment with plasmapheresis and mycophenolate mofetil. Transpl Int 2005; 18: 12981301.
  • 8
    Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004; 4: 10331041.
  • 9
    Nickeleit V, Mihatsch MJ. Kidney transplants, antibodies and rejection: Is C4d a magic marker? Nephrol Dial Transplant 2003; 18: 22322239.
  • 10
    Nickeleit V, Zeiler M, Gudat F, Thiel G, Mihatsch MJ. Detection of the complement degradation product C4d in renal allografts: Diagnostic and therapeutic implications. J Am Soc Nephrol 2002; 13: 242251.
  • 11
    Kluth-Pepper B, Schneeberger H, Lederer SR, Albert E, Land W, Feucht HE. Impact of humoral alloreactivity on the survival of renal allografts. Transplant Proc 1998; 30: 1772.
  • 12
    Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887895.
  • 13
    Melcher ML, Olson JL, Baxter-Lowe LA, Stock PG, Posselt AM. Antibody-mediated rejection of a pancreas allograft. Am J Transplant 2006; 6: 423428.
  • 14
    Ionescu DN, Girnita AL, Zeevi A et al. C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl Immunol 2005; 15: 6368.
  • 15
    Dankof A, Schmeding M, Morawietz L et al. Portal capillary C4d deposits and increased infiltration by macrophages indicate humorally mediated mechanisms in acute cellular liver allograft rejection. Virchows Arch 2005; 447: 8793.
  • 16
    Krukemeyer MG, Moeller J, Morawietz L et al. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004; 78: 6570.
  • 17
    Sawada T, Shimizu A, Kubota K, Fuchinoue S, Teraoka S. Lobular damage caused by cellular and humoral immunity in liver allograft rejection. Clin Transplant 2005; 19: 110114.
  • 18
    Schmeding M, Dankof A, Krenn V et al. C4d in acute rejection after liver transplantation—a valuable tool in differential diagnosis to hepatitis C recurrence. Am J Transplant 2006; 6: 523530.
  • 19
    Haga H, Egawa H, Fujimoto Y et al. Acute humoral rejection and C4d immunostaining in ABO blood type-incompatible liver transplantation. Liver Transpl 2006; 12: 457464.
  • 20
    Moeller J, Krukemeyer MG, Morawietz L et al. Molecular case report: IgVH analysis in acute humoral and cellular liver allograft rejection suggests a selected accumulation of effector B cells and plasma cells. Virchows Arch 2005; 446: 325332.